Overview
Spherix’s coverage of the inflammatory bowel disease market monitors the evolving landscape of ulcerative colitis and Crohn’s disease management with advanced therapies. We specifically track how new therapies influence changes in gastroenterologists’ attitudes and ultimately treatment decision-making.
Services Available
Trending market evolution
Crohn's Disease (US) - quarterly, n=100
Crohn's Disease (EU) - semiannual, n=250
Ulcerative Colitis (US) - quarterly, n=100
Ulcerative Colitis (EU) - semiannual, n=250
Exploring the patient journey
Biologic/Small Molecule New Starts in IBD (US) - n=1,000 patient charts
Biologic/Small Molecule Switching in IBD (US) - n=1,000 patient charts
Biologic/Small Molecule Switching in IBD (EU) - n=1,250 patient charts
Benchmarking new brand performance
Stelara (Janssen) in Ulcerative Colitis (US)
Zeposia (BMS) in Ulcerative Colitis (US)*
*Pending approvals and launch
Gauging impact of disruptive events
Multi-Specialty Impact of COVID-19 (US)
Pre-Advanced Systemic Therapies in IBD (US)